Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations

Area of Science:

• Oncology
• Medicinal Chemistry
• Drug Discovery

Background:

• Clinically acquired resistance to small molecule kinase inhibitors (SMKIs) presents a significant unmet need in cancer treatment.
• Six SMKIs targeting resistance mutations (e.g., Bcr-Abl T315I, EGFR T790M, ALK L1196M) have been approved.
• Overcoming on-target mutations is crucial for effective cancer therapy.

Purpose of the Study:

• To summarize key medicinal chemistry strategies for developing SMKIs against resistant mutations.
• To review approved SMKIs targeting specific on-target resistance mutations.
• To explore emerging strategies like allosteric inhibitors and PROTACs for future cancer therapies.

Main Methods:

• Review of medicinal chemistry literature and approved drug information.
• Analysis of strategies used to overcome steric hindrance and enhance target interactions.
• Discussion of covalent bonding and allosteric inhibition mechanisms.

Main Results:

• Identified strategies include avoiding steric hindrance, forming additional interactions, and covalent bond formation.
• Representative SMKIs targeting Bcr-Abl T315I, EGFR T790M, and ALK L1196M were analyzed.
• Allosteric kinase inhibitors and proteolysis targeting chimera (PROTACs) represent promising alternative strategies.

Conclusions:

• Medicinal chemistry offers diverse strategies to combat resistance to kinase inhibitors.
• Targeting resistance mutations with novel inhibitors is vital for improving cancer patient outcomes.
• Future research should focus on developing innovative approaches like PROTACs to address drug resistance.